Intercept Pharmaceuticals Analysis
| ICPTDelisted Stock | USD 19.00 0.00 0.00% |
Intercept Pharmaceuticals is overvalued with Real Value of 14.24 and Hype Value of 19.0. The main objective of Intercept Pharmaceuticals delisted stock analysis is to determine its intrinsic value, which is an estimate of what Intercept Pharmaceuticals is worth, separate from its market price. There are two main types of Intercept Pharmaceuticals' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Intercept Pharmaceuticals' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Intercept Pharmaceuticals' stock to identify patterns and trends that may indicate its future price movements.
The Intercept Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Intercept Pharmaceuticals is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Intercept Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Intercept Pharmaceuticals' ongoing operational relationships across important fundamental and technical indicators.
Intercept |
Intercept Stock Analysis Notes
About 81.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 4.26. Intercept Pharmaceuticals had not issued any dividends in recent years. Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company was incorporated in 2002 and is headquartered in New York, New York. Intercept Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 437 people. To learn more about Intercept Pharmaceuticals call Jerome Durso at 646 747 1000 or check out https://www.interceptpharma.com.Intercept Pharmaceuticals Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more delisted stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Intercept Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Intercept Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Intercept Pharmaceuticals is not yet fully synchronised with the market data | |
| Intercept Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Intercept Pharmaceuticals has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| The company reported the previous year's revenue of 285.71 M. Net Loss for the year was (174.86 M) with profit before overhead, payroll, taxes, and interest of 284.73 M. | |
| Intercept Pharmaceuticals currently holds about 404.78 M in cash with (26.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 13.58. | |
| Over 81.0% of the company shares are owned by institutional investors |
Intercept Pharmaceuticals Upcoming and Recent Events
Earnings reports are used by Intercept Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Intercept Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 25th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Intercept Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 794.36 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Intercept Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Intercept Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Intercept Profitablity
Intercept Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Intercept Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Intercept Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Intercept Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Intercept Pharmaceuticals' profitability requires more research than a typical breakdown of Intercept Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (0.19) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.02 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.02. Intercept Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Intercept Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Intercept Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Intercept Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Christian Weyer over six months ago Payment of 357 shares by Christian Weyer of Intercept Pharmaceuticals subject to Rule 16b-3 | ||
Christian Weyer over a year ago Payment of tradable shares by Christian Weyer of Intercept Pharmaceuticals subject to Rule 16b-3 |
Intercept Pharmaceuticals Predictive Daily Indicators
Intercept Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Intercept Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
About Intercept Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Intercept Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Intercept shares will generate the highest return on investment. We also built our delisted stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Delisted Stock such as Intercept Pharmaceuticals. By using and applying Intercept Stock analysis, traders can create a robust methodology for identifying Intercept entry and exit points for their positions.
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company was incorporated in 2002 and is headquartered in New York, New York. Intercept Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 437 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Intercept Pharmaceuticals to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Portfolio Optimization Now
Portfolio OptimizationCompute new portfolio that will generate highest expected return given your specified tolerance for risk |
| All Next | Launch Module |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Other Consideration for investing in Intercept Stock
If you are still planning to invest in Intercept Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intercept Pharmaceuticals' history and understand the potential risks before investing.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |